TABITHA HORN: Open Payments
NPI 1275122897 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,710 in 87 payments from 17 companies in 2025. Trend: 2023 $679 · 2024 $1,405 · 2025 $1,710
Food & beverage: $1,611Education: $99
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 13 | $426 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $379 |
| Novartis Pharmaceuticals Corporation | 7 | $176 |
| GlaxoSmithKline, LLC. | 10 | $166 |
| GENZYME CORPORATION | 8 | $137 |
| CSL Behring | 5 | $113 |
| Galderma Laboratories, L.P. | 1 | $52 |
| Genentech USA, Inc. | 2 | $46 |
| Blueprint Medicines Corporation | 2 | $43 |
| Lilly USA, LLC | 2 | $37 |
Products named: DUPIXENT, CUVITRU, HYQVIA, NUCALA, Hizentra, Rhapsido, Xolair, AYVAKIT.
Industry payments across KY — which companies pay providers there.
